An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of ProgenaMatrix™ in the Management of DFUs

NCT06292026

Diabetic Foot Ulcer

ACTIVE_NOT_RECRUITING NA

Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers

NCT00740922

Platelet-Derived Growth Factor Diabetic Foot Neoplasms

COMPLETED

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

NCT01154374

Diabetic Foot Ulcers

COMPLETED PHASE2

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU)

NCT06020664

Diabetic Foot Ulcer

SUSPENDED PHASE1

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

NCT03547635

Diabetic Foot Ulcer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pyoderma Gangrenosum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gevokizumab

Solution for subcutaneous injection (Part 1, Group B)

Group Type EXPERIMENTAL

gevokizumab

Intervention Type DRUG

Placebo

Solution for subcutaneous injection (Part 1, Group A)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

gevokizumab open-label

Solution for subcutaneous injection (Part 2, Open-label)

Group Type EXPERIMENTAL

gevokizumab open-label

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gevokizumab

Intervention Type DRUG

Placebo

Intervention Type DRUG

gevokizumab open-label

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A clinical diagnosis of classic pyoderma gangrenosum
* An active pyoderma gangrenosum ulcer
* Contraceptive measures adequate to prevent pregnancy during the study

Exclusion Criteria

* Clinical evidence of acutely infected pyoderma gangrenosum
* History of allergic or anaphylactic reactions to monoclonal antibodies
* History of recurrent or chronic systemic infections
* Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No